John Schreiber
Neurology with Special Qualifications in Child Neurology · Washington, DCNPI 1194982082
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,617 of the $45,412 with a category attached, or 60.8%. 14 manufacturers reported payments, led by UCB, Inc. at 58.2% of the total. Reporting peaked in 2022 at $19,914 and has fallen 69.2% since, to $6,135 in 2025. Among neurology with special qualifications in child neurology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $516.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$26K
- Immedica Pharma US, Inc.$13K
- Zogenix Inc.$4K
- Neurocrine Biosciences, Inc.$1K
- Neurelis, Inc.$547
- Livanova USA, Inc.$284
- plus $498 from 8 others
Across 42 payments — averaging $2684.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$65K
- PTC Therapeutics, Inc.$26K
- Jazz Pharmaceuticals Inc.$13K
- Eisai Inc.$6K
- Biomarin Pharmaceutical Inc.$2K
- Neurocrine Biosciences, Inc.$600
What the payments were for
- Consulting fees$11,56325%
- Speaking & faculty fees$27,61761%
- Travel & lodging$2,8306%
- Food & beverage$3,4027%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 38 | $26,446 |
| Immedica Pharma US, Inc. | 20 | $12,907 |
| Zogenix Inc. | 5 | $3,510 |
| Neurocrine Biosciences, Inc. | 4 | $1,221 |
| Neurelis, Inc. | 5 | $547 |
| Livanova USA, Inc. | 6 | $284 |
| Biomarin Pharmaceutical Inc. | 3 | $167 |
| Medtronic | 1 | $145 |
| Acadia Pharmaceuticals Inc | 1 | $57 |
| Lundbeck LLC | 1 | $49 |
| EPI Health, LLC | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Eisai Inc. | 1 | $17 |
| Aquestive Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,412 in reported general payments places this provider in the 95th percentile of 26 neurology with special qualifications in child neurology providers in District of Columbia.
See all neurology with special qualifications in child neurology providers in District of Columbia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 20 | $80,339 |
| Divalproex Sodium | 23 | $1,576 |
| Lamotrigine | 18 | $310 |
| Topiramate | 17 | $212 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Washington
- Sarah WrightWashington$53K
- Andrea GropmanWashington$36K
- Benjamin SiegelWashington$5K
- Laura TochenWashington$2K
- Stephen SharpWashington$959
- Melanie OrtizWashington$796
- Mejdi NajjarWashington$620
- Tarannum LateefWashington$600
- Meaghan KellyWashington$459
- Christine TranWashington$311
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.